Filing Flows

Filing Flows › Companies › RenovoRx › Cash flow

RenovoRx cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.6M in Q3 2026 · −$12.2M over twelve months

Operating cash flow−$2.5M
Capital spending−$19K
Free cash flow−$2.6M
Cash conversion cycle-217 days

Analysis

In Q3 2026, RenovoRx generated −$2.5M of operating cash flow and spent $19K on capital projects, leaving free cash flow of −$2.6M. That is $288K less than in Q3 2025 (−$2.3M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$12.1M; the largest uses were operating cash flow ($12.1M), capital spending ($90K); besides operations, cash came from shares issued ($10.0M), other financing ($2.6M); the cash balance rose by $360K.

Operating cash flow was −$2.5M against net income of −$3.6M. The largest differences: stock-based pay +$469K, accrued liabilities +$101K, payables +$91K.

Its cash conversion cycle was -217 days (receivables 47 + inventory 177 − payables 441): suppliers fund its working capital.

Free cash flow

RenovoRx: free cash flow by quarterRenovoRx: free cash flow by quarter−$2.4MQ4 2024−$3.4MQ1 2025−$2.3MQ2 2025−$2.3MQ3 2025−$3.0MQ4 2025−$3.7MQ1 2026−$2.9MQ2 2026−$2.6MQ3 2026
Operating cash flow less capital spending.
RenovoRx: operating cash flow against capital spendingRenovoRx: operating cash flow against capital spendingOperating cash flowCapital spending−$2.4M$0Q4 2024−$3.4M$2KQ1 2025−$2.3M$0Q2 2025−$2.3M$0Q3 2025−$3.0M$0Q4 2025−$3.7M$0Q1 2026−$2.9M$71KQ2 2026−$2.5M$19KQ3 2026
Latest (Q3 2026): Operating cash flow −$2.5M, Capital spending $19K.

Capital allocation, year by year

RenovoRx: where the cash came from (up) and went (down), by fiscal yearRenovoRx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$5.9MFY2021: Net borrowing $2.0MFY2021: Shares issued $14.7M$16.6MFY2021FY2022: Operating cash flow −$8.8MFY2022: Shares issued $42K$42KFY2022FY2023: Operating cash flow −$10.3MFY2023: Shares issued $5.0M$5.0MFY2023FY2024: Operating cash flow −$9.1MFY2024: Shares issued $17.3MFY2024: Capital spending −$12K$17.3MFY2024FY2025: Operating cash flow −$11.0MFY2025: Shares issued $12.1MFY2025: Capital spending −$2K$12.1MFY2025
Over these 5 years operating cash flow totalled −$45.1M; the largest uses were operating cash flow ($45.1M) and capital spending ($14K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$10.4M
Debtnone
Net cash$10.4M
Cash runway10 months

RenovoRx is burning cash: its operations consume cash, a free cash flow of −$12.2M a year at the current rate against $10.4M of cash and investments: a runway of about 10 months before any new financing.

Where the cash came from and went

RenovoRx: sources (+) and uses (−) of cash, Q3 2026RenovoRx: sources (+) and uses (−) of cash, Q3 2026Other financing$3.5MOperating cash flow−$2.5MCash drawn (+) / kept (−)−$925KCapital spending−$19KShares issued$5K
RenovoRx: sources (+) and uses (−) of cash, TTM to Q3 2026RenovoRx: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$12.1MShares issued$10.0MOther financing$2.6MCash drawn (+) / kept (−)−$360KCapital spending−$90K

From profit to cash

RenovoRx: net income to operating cash flow, Q3 2026RenovoRx: net income to operating cash flow, Q3 2026Net income−$3.6MDepreciation & amortization$5KStock-based pay$469KInventory$42KPayables$91KAccrued liabilities$101KPrepaid and other assets−$42KOperating cash flow−$2.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202647177441-217
Q2 202638242632-351
Q1 2026333041028-690
Q4 2025607572740-1923

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$2.5M−$19K$5K−$925K−$2.6M
Q2 2026−$2.9M−$71K—$2.9M−$2.9M
Q1 2026−$3.7M—$10.0M−$5.3M−$3.7M
Q4 2025−$3.0M——$3.0M−$3.0M
Q3 2025−$2.3M——$2.3M−$2.3M
Q2 2025−$2.3M—$9K$2.3M−$2.3M
Q1 2025−$3.4M−$2K$12.1M−$7.4M−$3.4M
Q4 2024−$2.4M——$2.4M−$2.4M

RenovoRx: income statement and cash flow

RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%. The chart follows the revenue to costs, profit and cash.

RenovoRx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.